Genomic Analysis and Clinical Correlations of Non-Small Cell Lung Cancer (NSCLC) Brain Metastasis (BM)-Reference-Cited by-同舟云学术

Genomic Analysis and Clinical Correlations of Non-Small Cell Lung Cancer (NSCLC) Brain Metastasis (BM)

Published:2023-01-24 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Skakodub Anna¹,Walch Henry¹,Tringale Kathryn¹,Eichholz Jordan¹,Imber Brandon¹,Vasudevan Harish²,Li Bob³^ORCID,Moss Nelson¹,Yu Kenny¹,Mueller Boris¹,Powell Simon¹^ORCID,Razavi Pedram¹^ORCID,Yu Helena⁴^ORCID,Reis-Filho Jorge¹^ORCID,Gomez Daniel⁵,Schultz Nikolaus⁶^ORCID,Pike Luke¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center

2. University of California San Francisco

3. Memorial Sloan Kettering Cancer Center; Weill Cornell Medicine

4. Memorial Sloan-Kettering Cancer Center

5. The University of Texas MD Anderson Cancer Center

6. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Abstract

Abstract Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical data, and a lack of comparison with paired extracranial specimens. Here we report a cohort of 233 patients with resected and sequenced (MSK-IMPACT) NSCLC BM and comprehensive clinical data. With matched samples (47 primary tumor, 42 extracranial metastatic), we showed CDKN2A/B deletions and cell cycle pathway alterations to be enriched in the BM samples. Meaningful clinico-genomic correlations were noted, namely EGFR alterations in leptomeningeal disease (LMD) and MYC amplifications in multifocal regional brain progression. Patients who developed early LMD frequently had uncommon, multiple, and persistently detectable EGFR driver mutations. The distinct mutational patterns identified in BM specimens compared to other tissue sites suggest specific biologic underpinnings of intracranial progression.

Publisher

Research Square Platform LLC

Reference28 articles.

1. “Cancer Statistics, 2018;Siegel Rebecca L;CA: A Cancer Journal for Clinicians,2018

2. Cagney, Daniel N., Allison M. Martin, Paul J. Catalano, Amanda J. Redig, Nancy U. Lin, Eudocia Q. Lee, Patrick Y. Wen, et al. 2017. “Incidence and Prognosis of Patients with Brain Metastases at Diagnosis of Systemic Malignancy: A Population-Based Study.” Neuro-Oncology 19 (11): 1511–21.

3. De Mattos-Arruda, Leticia, Regina Mayor, Charlotte K. Y. Ng, Britta Weigelt, Francisco Martínez-Ricarte, Davis Torrejon, Mafalda Oliveira, et al. 2015. “Cerebrospinal Fluid-Derived Circulating Tumour DNA Better Represents the Genomic Alterations of Brain Tumours than Plasma.” Nature Communications 6 (November): 8839.

4. “Genetic Heterogeneity and Actionable Mutations in HER2-Positive Primary Breast Cancers and Their Brain Metastases;Ng Mattos-Arruda, Leticia,CharlotteKY;Oncotarget,2018

5. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets;Brastianos Priscilla K;Cancer Discovery,2015